Wire · opportunities
VETmAb Biosciences Announces Positive Clinical Proof-of-Concept Results for Long-Acting ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
VETmAb Biosciences announced positive clinical proof-of-concept results for VMB-C001a, a long-acting anti-IL-23 antibody targeting canine chronic inflammatory enteropathy, showing a 77.8% treatment success rate versus 30% for placebo. The drug has been granted eligibility for the FDA Center for Veterinary Medicine's expanded conditional approval pathway, allowing earlier marketing while final approval studies complete.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Your veterinary biologics startup can now consider the FDA’s expanded conditional approval as a fast-track route to market for breakthrough pet therapies. This opens a direct path to revenue before full approvals kick in, shifting your development timelines.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics